O
Oncomatryx Biopharma
Biopharmaceutical company focused on the tumor microenvironment, and developeds precision drugs and diagnostic devices
About Oncomatryx Biopharma
Oncomatryx Biopharma is a clinical-stage biopharmaceutical company that develops personalized treatments for invasive cancers, with a focus on targeting the tumor microenvironment. The company is engaged in the development of precision drugs and diagnostic devices for cancers such as pancreatic and invasive breast cancer, which are associated with high mortality rates.
The company's core activities include the discovery, development, and commercialization of novel medicines. Its business model is centered on research and development, followed by clinical trials and subsequent commercialization of its proprietary drugs and diagnostic tools. Oncomatryx Biopharma has a pipeline of antibody-drug conjugates aimed at the tumor microenvironment. The company has secured $52.5 million in funding over three rounds from three investors to support its research and development efforts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Derio, Spain
- Employees
- 39
- Open positions
- 5
- Dealroom signal
- 91.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, EIC, Biotech and Pharma, Horizon Europe, DT and LS, eu apply ai, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest May 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Mar 2025 | $2.5M | — | European Innovation Council | — |
| LATE VCOther financing | Jan 2025 | $28M | $110M | CDTI Innvierte | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Oncomatryx Biopharma is 2.9K monthly website visits, up 20.8% over the last three months. Oncomatryx Biopharma's team grew 21.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Provincial Council of Bizkaia
European Innovation Council
Series A4 investors entered at this stage
Gestión de Capital Riesgo del País Vasco
Deloitte
Kutxabank
Ekarpen
Series B and later1 investor entered at this stage
CDTI Innvierte
Other known investors1 additional known investor
BEAZ
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oncomatryx Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oncomatryx Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.